Catalent (NYSE:CTLT) Lowered to “Hold” at Baird R W

Baird R W lowered shares of Catalent (NYSE:CTLT) from a strong-buy rating to a hold rating in a report published on Tuesday morning, Zacks.com reports.

CTLT has been the topic of several other reports. Robert W. Baird reaffirmed a neutral rating and issued a $63.50 target price on shares of Catalent in a research report on Tuesday. StockNews.com assumed coverage on Catalent in a research report on Wednesday, September 18th. They set a sell rating on the stock. Royal Bank of Canada reiterated a sector perform rating and set a $63.50 price objective on shares of Catalent in a research note on Thursday, July 11th. William Blair reissued a market perform rating on shares of Catalent in a research report on Tuesday, September 3rd. Finally, Barclays lifted their target price on Catalent from $47.00 to $63.00 and gave the stock an equal weight rating in a research report on Friday, June 28th. One equities research analyst has rated the stock with a sell rating and eight have given a hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of Hold and a consensus target price of $59.83.

Catalent Stock Performance

Catalent stock opened at $60.34 on Tuesday. The stock has a fifty day moving average price of $59.69 and a 200 day moving average price of $57.33. The company has a current ratio of 2.52, a quick ratio of 1.96 and a debt-to-equity ratio of 1.35. Catalent has a 52 week low of $31.80 and a 52 week high of $61.20. The firm has a market capitalization of $10.92 billion, a P/E ratio of -9.89, a PEG ratio of 2.32 and a beta of 1.15.

Catalent (NYSE:CTLT) last announced its quarterly earnings data on Thursday, August 29th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.13. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. The business had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.23 billion. Equities research analysts anticipate that Catalent will post 0.85 earnings per share for the current year.

Insider Buying and Selling

In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of the business’s stock in a transaction on Monday, July 29th. The shares were sold at an average price of $58.76, for a total transaction of $534,010.88. Following the completion of the sale, the chief executive officer now owns 177,521 shares in the company, valued at $10,431,133.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CEO Alessandro Maselli sold 9,088 shares of the stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $58.76, for a total transaction of $534,010.88. Following the sale, the chief executive officer now directly owns 177,521 shares in the company, valued at approximately $10,431,133.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Matti Masanovich sold 2,993 shares of the business’s stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $56.74, for a total value of $169,822.82. Following the transaction, the chief financial officer now owns 33,871 shares of the company’s stock, valued at approximately $1,921,840.54. The disclosure for this sale can be found here. Insiders have sold 15,403 shares of company stock worth $902,503 over the last ninety days. 0.31% of the stock is owned by insiders.

Institutional Trading of Catalent

A number of large investors have recently modified their holdings of CTLT. Nisa Investment Advisors LLC grew its position in Catalent by 1.7% in the 2nd quarter. Nisa Investment Advisors LLC now owns 11,013 shares of the company’s stock worth $619,000 after purchasing an additional 185 shares during the last quarter. Lindbrook Capital LLC grew its holdings in Catalent by 79.4% in the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after buying an additional 208 shares in the last quarter. GAMMA Investing LLC increased its position in Catalent by 25.9% in the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after acquiring an additional 212 shares during the period. Czech National Bank raised its stake in Catalent by 0.7% during the 1st quarter. Czech National Bank now owns 31,801 shares of the company’s stock valued at $1,795,000 after acquiring an additional 228 shares in the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd boosted its position in Catalent by 1.4% during the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,238 shares of the company’s stock worth $1,082,000 after acquiring an additional 257 shares during the period.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.